|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Pfizer_Inc.
|
|
gptkbp:approves
|
gptkb:1991
|
|
gptkbp:brand
|
gptkb:Zoloft
gptkb:Sertralin
gptkb:Zoloft_Oral_Solution
Lustral
Serlain
|
|
gptkbp:category
|
gptkb:C
|
|
gptkbp:clinical_trial
|
comparative studies
efficacy studies
safety studies
long-term studies
FDA approval studies
|
|
gptkbp:contraindication
|
MAO inhibitors
hypersensitivity to sertraline
|
|
gptkbp:dosage_form
|
gptkb:tablet
gptkb:item
100 mg
50 mg
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Zoloft
|
|
gptkbp:ingredients
|
sertraline
C17 H17 Cl2 N
|
|
gptkbp:interacts_with
|
gptkb:beer
gptkb:warfarin
NSAI Ds
other SSR Is
|
|
gptkbp:is_a_route_for
|
oral
|
|
gptkbp:is_atype_of
|
N06 A B06
|
|
gptkbp:is_used_for
|
gptkb:historical_event
gptkb:post-traumatic_stress_disorder
anxiety disorders
obsessive-compulsive disorder
panic disorder
|
|
gptkbp:legal_issue
|
prescription only
|
|
gptkbp:lifespan
|
24 hours
|
|
gptkbp:manufacturer
|
gptkb:Pfizer
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:side_effect
|
dizziness
nausea
insomnia
dry mouth
sexual dysfunction
|
|
gptkbp:symptoms
|
anxiety
dizziness
irritability
mood swings
discontinuation syndrome
|
|
gptkbp:traded_on
|
gptkb:sertraline_hydrochloride
|
|
gptkbp:type_of
|
79617-96-2
|
|
gptkbp:type_of_care
|
important for effectiveness
|